{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T16:43:30Z","timestamp":1719938610841},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.pupt.2017.01.009","type":"journal-article","created":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T05:48:51Z","timestamp":1484977731000},"page":"12-19","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Robert","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana R.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hynds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshid","family":"Homayoun-Valiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Tabberer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2017.01.009_bib1","unstructured":"The global initiative for chronic obstructive lung disease (GOLD) revised (2016). Available at: http:\/\/www.goldcopd.com)."},{"issue":"11","key":"10.1016\/j.pupt.2017.01.009_bib2","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.pupt.2017.01.009_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/15412555.2011.648030","article-title":"Chronic obstructive pulmonary disease and socioeconomic status: a systematic review","volume":"9","author":"Gershon","year":"2012","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2017.01.009_bib4","first-page":"141","article-title":"Chronic airflow limitation in developing countries: burden and priorities","volume":"2","author":"A\u00eft-Khaled","year":"2007","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"10.1016\/j.pupt.2017.01.009_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1183\/09031936.00138606","article-title":"Global alliance against chronic respiratory diseases","volume":"29","author":"Bousquet","year":"2007","journal-title":"Eur. Respir. J."},{"issue":"Issue 8","key":"10.1016\/j.pupt.2017.01.009_bib6","article-title":"Combination therapy of inhaled steroids and long-acting beta2-agonists compared to inhaled steroids alone for people with COPD","author":"Nannini","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.pupt.2017.01.009_bib7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"For ATS\/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.pupt.2017.01.009_bib8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2017.01.009_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1378\/chest.06-0702","article-title":"Development and validation of an Improved, COPD-Specific version of the St. George respiratory questionnaire","volume":"132","author":"Meguro","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2017.01.009_bib10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD assessment test (CAT)","volume":"34","author":"Jones","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.pupt.2017.01.009_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","article-title":"Minimal important difference of the transition dyspnoea index in a multinational clinical trial","volume":"21","author":"Witek","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.01.009_bib12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.01.009_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","article-title":"Minimum clinically important difference for the COPD assessment test: a prospective analysis","volume":"2","author":"Kon","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2017.01.009_bib14","unstructured":"GSK clinical study register, An exercise endurance study to evaluate the effects of treatment of chronic obstructive pulmonary disease (COPD) patients with a dual bronchodilator: GSK573719\/GW642444, Study B. http:\/\/www.gsk-clinicalstudyregister.com\/study\/114418?study_ids=DB2114418#ps."},{"issue":"3","key":"10.1016\/j.pupt.2017.01.009_bib15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 microg)\/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.pupt.2017.01.009_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1183\/09031936.00191810","article-title":"INTENSITY study investigators. Blinded 12-week comparison of once daily indacaterol and tiotropium in COPD","volume":"38","author":"Buhl","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.pupt.2017.01.009_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.rmed.2011.02.008","article-title":"INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study","volume":"105","author":"Korn","year":"2011","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.pupt.2017.01.009_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.01.009_bib19","author":"GSK clinical study register"},{"key":"10.1016\/j.pupt.2017.01.009_bib20","first-page":"1","article-title":"Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients","volume":"26","author":"Daley-Yates","year":"2013","journal-title":"J.\u00a0Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2017.01.009_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2014.07.001","article-title":"Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler","author":"Mehta","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2017.01.009_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pupt.2016.09.002","article-title":"Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma","volume":"41","author":"Chan","year":"2016","journal-title":"Pulm. Pharmacol. Ther."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553916300864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553916300864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T23:25:17Z","timestamp":1536103517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553916300864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":22,"alternative-id":["S1094553916300864"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2017.01.009","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2017.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}